Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
Recruiting
National Cancer Institute (NCI)
Phase 2
2021-11-15
This phase II trial studies the effects of leflunomide in treating African-American and
European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to
decrease the body's immune response and may delay the symptoms of multiple myeloma in
patients of African-American and European decent.
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
Recruiting
City of Hope Medical Center
Phase 2
2021-11-15
This phase II trial studies the effects of leflunomide in treating African-American and
European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to
decrease the body's immune response and may delay the symptoms of multiple myeloma in
patients of African-American and European decent.
Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies
Not yet recruiting
National Cancer Institute (NCI)
Phase 1
2022-12-10
This phase I trial tests the safety and side effects of leflunomide in combination with
steroids in treating patients with acute graft versus host disease who have undergone done
stem cell transplant for blood cancers (hematologic malignancies). Sometimes the transplanted
cells from a donor can attack the body's normal cells (called graft-versus-host disease).
Leflunomide and steroids are immunosuppressive drugs that work in different ways to lower the
body's immune response so that the new donor immune cells do not attack the body's normal
cells. Giving leflunomide in combination with steroids may help treat acute graft versus host
disease in patients after stem cell transplant for hematologic malignancies.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
